title: Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
abstract: In 1968 the Food and Drug Administration (FDA) established the Adverse Event Reporting System (AERS) database containing data on adverse events (AEs) reported by patients, health care providers, and other sources through a spontaneous reporting system. FDA uses AERS for monitoring the safety of the drugs on the market after approval. Most statistical methods that are available in the literature to analyze large postmarket drug safety data for identifying drug-event combinations with disproportionately high frequencies are designed to explore signals of a single drug-AE combination, but not signals including a drug class or a group of AEs simultaneously. Those methods are also not designed to control type I error and are subject to high false discovery rates. In this paper, we first briefly review a recently developed method, known as the likelihood ratio test (LRT)-based method, which has been demonstrated to control the family-wise type I error and false discovery rates. By introducing a concept of weight matrix for the drugs (or for AEs), we then extend the LRT method for detecting signals including a class of drugs (or AEs) in addition to detecting signals of single drug (or AE). A simplified Bayesian method is also proposed and compared with LRT method. The proposed methods are applied to study the signal patterns of drug classes, namely, the gadolinium drug class for magnetic resonance imaging (MRI) and statins for hypercholesterolemia, over different time periods, using the datasets with only suspect drugs and with both suspect and concomitant drugs from the AERS database. The signals detected by the statistical methods can be confirmed by signals detected across different databases, existing medical evidence from research or regulatory resources, prospective biological studies, and also through simulation as illustrated in the application.
authors: Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, USA. lan.huang@fda.hhs.gov
authors: Lan
authors: L
authors: Huang
authors: Jyoti
authors: J
authors: Zalkikar
authors: Ram C
authors: RC
authors: Tiwari
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards* / Q000706:statistics & numerical data; D016208:Databases, Factual / Q000592:standards* / Q000706:statistics & numerical data; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D016013:Likelihood Functions; D004364:Pharmaceutical Preparations / Q000145:classification*; D013223:Statistics as Topic / Q000379:methods* / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards* / Q000706:statistics & numerical data
chemical_list: D004364:Pharmaceutical Preparations